DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)]

Biochemical Pharmacology

Volumn 73, Issue 12, 2007, Pages 1887-1900

  Brabec, Viktor ^a   Christofis, Petros ^a   Slámová, Martina ^a   Kostrhunová, Hana ^a   Nováková, Olga ^a   Najajreh, Yousef ^b   Gibson, Dan ^b   Kašpárková, Jana ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cytotoxicity; Dinuclear platinum complex; DNA cross links; DNA modification; DNA protein cross links; Platinum antitumor drug

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; PIPERAZINE DERIVATIVE; PLATINUM COMPLEX; TRANSPLATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BASE PAIRING; BIOPHYSICS; CONTROLLED STUDY; CROSS LINKING; CULTURE MEDIUM; DRUG DESIGN; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG SPECIFICITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CATTLE; CELL LINE, TUMOR; CISPLATIN; CROSS-LINKING REAGENTS; DNA; DNA ADDUCTS; DNA, SUPERHELICAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; OVARIAN NEOPLASMS; PIPERAZINES; PLATINUM; PLATINUM COMPOUNDS; POLAROGRAPHY; SPECTROMETRY, FLUORESCENCE; TEMPERATURE; TRANSCRIPTION, GENETIC;

EID: 34247611426     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.03.003     Document Type: Article

References (64)

1. Brabec V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol 71 (2002) 1-68
2. Brabec V., and Kasparkova J. DNA interactions of platinum anticancer drugs. Recent advances and mechanisms of action. In: Perez-Martin J.-M., Fuertes M.A., and Alonso C. (Eds). Metal compounds in cancer chemotherapy (2005), Research Signpost, Trivandrum, Kerala, India 187-218
3. Barnes K.R., and Lippard S.J. Cisplatin and related anticancer drugs: Recent advances and insights. Metal ions in biological systems, vol. 42: metal complexes in tumor diagnosis and as anticancer agents (2004), Marcel Dekker, New York p. 143-77
4. Wozniak K., and Walter Z. Induction of DNA-protein cross-links by platinum compounds. Z Naturforsch C 55 (2000) 731-736
5. Wong E., and Giandomenico C.M. Current status of platinum-based antitumor drugs. Chem Rev 99 (1999) 2451-2466
6. Boulikas T., and Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 10 (2003) 1663-1682 [Review]
7. McKeage M.J. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Exp Opin Invest Drugs 14 (2005) 1033-1046
8. Cohen S.M., and Lippard S.J. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67 (2001) 93-130
9. Zwelling L.A., Anderson T., and Kohn K.W. DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II)diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 39 (1979) 365-369
10. Olinski R., Wedrychovski A., Schmidt W.N., Briggs R.C., and Hnilica L.S. In vivo DNA-protein cross-linking by cis- and trans-diamminedichloroplatinum(II). Cancer Res 47 (1987) 201-205
11. Scovell W.M., Muirhead N., and Kroos L.R. Cis-diamminedichloroplatinum(II) selectively cross-links high mobility group proteins 1 and 2 to DNA in micrococcal nuclease accessible regions of chromatin. Biochem Biophys Res Commun (1987) 142
12. Yamamoto J., Miyagi Y., Kawanishi K., Yamada S., Kodama J., Yoshinouchi M., et al. Effect of cisplatin on cell death and DNA crosslinking in rat mammary adenocarcinoma in vitro. Acta Med Okayama 53 (1999) 201-208
13. Farrell N., Povirk L.F., Dange Y., DeMasters G., Gupta M.S., Kohlhagenc G., et al. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. Biochem Pharmacol 68 (2004) 857-866
14. Farrell N. Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. In: Sigel A., and Sigel H. (Eds). Metal ions in biological systems (1996), Marcel Dekker, Inc., New York 603-639
15. Natile G., and Coluccia M. Antitumor active trans-platinum compounds. In: Sigel A., and Sigel H. (Eds). Metal ions in biological systems (2004), Marcel Dekker, Inc., New York 209-250
16. 2(amine)(isopropylamine)] compounds: cytotoxic activity and apoptosis induction in ras-transformed cells. J Med Chem 42 (1999) 4264-4268
17. Coluccia M., Nassii F., Loseto F., Boccarelli A., Marigió M.A., Giordano D., et al. A trans-platinum complex showing higher antitumor activity than the cis congeners. J Med Chem 36 (1993) 510-512
18. Farrell N. Polynuclear platinum drugs. In: Sigel A., and Sigel H. (Eds). Metal ions in biological systems (2004), Marcel Dekker, Inc., New York 251-296
19. Wheate N.J., and Collins J.G. Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr Med Chem: Anti-Cancer Agents 5 (2005) 267-279
20. Wheate N.J., and Collins J.G. Multi-nuclear platinum complexes as anti-cancer drugs. Coord Chem Rev 241 (2003) 133-145
21. Komeda S., Lutz M., Spek A., Chikuma M., and Reedijk J. New antitumor-active azole-bridged dinuclear platinum(II) complexes: synthesis, characterization, crystal structures, and cytotoxic studies. Inorg Chem 39 (2000) 4230-4236
22. Brabec V., and Palecek E. Interaction of nucleic acids with electrically charged surfaces. II. Conformational changes in double-helical polynucleotides. Biophys Chem 4 (1976) 76-92
23. Kim S.D., Vrana O., Kleinwächter V., Niki K., and Brabec V. Polarographic determination of subnanogram quantities of free platinum in reaction mixture with DNA. Anal Lett 23 (1990) 1505-1518
24. Brabec V., Reedijk J., and Leng M. Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry 31 (1992) 12397-12402
25. Kasparkova J., Farrell N., and Brabec V. Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J Biol Chem 275 (2000) 15789-15798
26. Brabec V., and Leng M. DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci USA 90 (1993) 5345-5349
27. Lemaire M.A., Schwartz A., Rahmouni A.R., and Leng M. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc Natl Acad Sci USA 88 (1991) 1982-1985
28. Butour J.L., and Macquet J.P. Differentiation of DNA-platinum complexes by fluorescence. The use of an intercalating dye as a probe. Eur J Biochem 78 (1977) 455-463
29. 2]. Eur J Biochem 202 (1991) 975-980
30. Farrell N., Qu Y., Feng L., and Van Houten B. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry 29 (1990) 9522-9531
31. Roberts J.D., Vanhouten B., Qu Y., and Farrell N.P. Interaction of novel bis(platinum) complexes with DNA. Nucleic Acids Res 17 (1989) 9719-9733
32. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48 (1988) 589-601
33. Kasparkova J., Novakova O., Vrana O., Farrell N., and Brabec V. Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking. Biochemistry 38 (1999) 10997-11005
34. Zaludova R., Zakovska A., Kasparkova J., Balcarova Z., Kleinwächter V., Vrana O., et al. DNA interactions of bifunctional dinuclear platinum(II) antitumor agents. Eur J Biochem 246 (1997) 508-517
35. Brabec V., Boudny V., and Balcarova Z. Monofunctional adducts of platinum(II) produce in DNA a sequence-dependent local denaturation. Biochemistry 33 (1994) 1316-1322
36. Corda Y., Anin M.F., Leng M., and Job D. RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II). Biochemistry 31 (1992) 1904-1908
37. Corda Y., Job C., Anin M.F., Leng M., and Job D. Transcription by eucaryotic and procaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 30 (1991) 222-230
38. Novakova O., Vrana O., Kiseleva V.I., and Brabec V. DNA interactions of antitumor platinum(IV) complexes. Eur J Biochem 228 (1995) 616-624
39. Brabec V., Kasparkova J., Vrana O., Novakova O., Cox J.W., Qu Y., et al. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry 38 (1999) 6781-6790
40. 2]. Nucleic Acids Res 24 (1996) 336-341
41. 3)(quinoline)]. Eur J Biochem 254 (1998) 547-557
42. Mullins S.T., Annan N.K., Cook P.R., and Lowe G. Bisintercalators of DNA with a rigid linker in an extended configuration. Biochemistry 31 (1992) 842-849
43. Carpenter M.L., Lowe G., and Cook P.R. The structure of 4-way DNA junctions: specific binding of bis-intercalators with rigid linkers. Nucleic Acids Res 24 (1996) 1594-1601
44. Eastman A., and Barry M.A. Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry 26 (1987) 3303-3307
45. Fichtinger-Schepman A.M.J., Van der Veer J.L., Den Hartog J.H.J., Lohman P.H.M., and Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24 (1985) 707-713
46. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34 (1987) 155-166
47. Kasparkova J., Marini V., Najajreh Y., Gibson D., and Brabec V. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Biochemistry 42 (2003) 6321-6332
48. Zaludova R., Kleinwächter V., and Brabec V. The effect of ionic strength on melting of DNA modified by platinum(II) complexes. Biophys Chem 60 (1996) 135-142
49. Cohen G.L., Bauer W.R., Barton J.K., and Lippard S.J. Binding of cis and trans dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix. Science 203 (1979) 1014-1016
50. Bellon S.F., Coleman J.H., and Lippard S.J. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 30 (1991) 8026-8035
51. Keck M.V., and Lippard S.J. Unwinding of supercoiled DNA by platinum ethidium and related complexes. J Am Chem Soc 114 (1992) 3386-3390
52. Scovell W.M., and Collart F. Unwinding of supercoiled DNA by cis- and trans-diamminedichloro-platinum(II): influence of the torsional strain on DNA unwinding. Nucleic Acids Res 13 (1985) 2881-2895
53. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47 (1987) 414-418
54. Najajreh Y., Perez J.M., Navarro-Ranninger C., and Gibson D. Novel soluble cationic trans-diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J Med Chem 45 (2002) 5189-5195
55. Ramos-Lima F.J., Vrana O., Quiroga A.G., Navarro-Ranninger C., Halamikova A., Rybnickova H., et al. Structural characterization, DNA interactions, and cytotoxicity of new transplatin analogues containing one aliphatic and one planar heterocyclic amine ligand. J Med Chem 49 (2006) 2640-2651
56. Kloster M., Kostrhunova H., Zaludova R., Malina J., Kasparkova J., Brabec V., et al. Trifunctional dinuclear platinum complexes as DNA-protein cross-linking agents. Biochemistry 43 (2004) 7776-7786
57. Jamieson E.R., and Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99 (1999) 2467-2498
58. Berge T., Haken E.L., Waring M.J., and Henderson R.M. The binding mode of the DNA bisintercalator luzopeptin investigated using atomic force microscopy. J Struct Biol 142 (2003) 241-246
59. Van Houten B., Illenye S., Qu Y., and Farrell N. Homodinuclear (Pt, Pt) and heterodinuclear (Ru, Pt) metal compounds as DNA-protein cross-linking agents: potential suicide DNA lesions. Biochemistry 32 (1993) 11794-11801
60. Rink S.M., Yarema K.J., Solomon M.S., Paige L.A., Tadayoni-Rebek B.M., Essigmann J.M., et al. Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Proc Natl Acad Sci USA 93 (1996) 15063-15068
61. He C., and Verdine G.L. Trapping distinct structural states of a protein/DNA interaction through disulfide crosslinking. Chem Biol 9 (2002) 1297-1303
62. Travers A. Mapping histone positions in chromatin by protein-directed DNA crosslinking and cleavage. In: Travers A., and Buckle M. (Eds). DNA-protein interactions (2000), Oxford University Press, Oxford 229-238
63. Bancroft D.P., Lepre C.A., and Lippard S.J. Pt-195 NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA. J Am Chem Soc 112 (1990) 6860-6871
64. Chvalova K., Brabec V., and Kasparkova J. Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 35 (2007) 1812-1821